Eduard Panosyan, MD

Investigator, The Lundquist Institute
Assistant Clinical Professor of Pediatrics, Pediatric Hematology and Oncology, David Geffen School of Medicine at UCLA


Brain Tumors

Research Description

Dr. Panosyan is the Chief of Pediatric Hematology-Oncology Division at Harbor-UCLA Medical Center providing comprehensive care for children with blood and neoplastic diseases. He is the Principal Investigator of Children’s Oncology Group (COG) at LA BioMed/HUMC. His current clinical research focuses on enrollment of pediatric oncology patients for COG registration and therapeutic studies. He is also Medical Director of CCS Specialty Care Center at HUMC for pediatric patients with Sickle Cell Disease, and is involved in Hematology clinical research. Dr. Panosyan’s basic science research interests are in the area of neuro-oncology – particularly exploration of anti-metabolic strategies targeting amino-acids for brain tumor therapeutics development.
Research Interests


  • MD, 1997, Yerevan State Medical University, Armenia

Recent and/or Significant Publications

Sanghez V, Chen M, Li S, Chou TF, Iacovino M, Lin HJ, Lasky JL and Panosyan EH. Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma. Anticancer Res. 2018 May;38(5):2627-2634.
Panosyan E, Lin HJ, Koster J, Lasky JL. In search of druggable targets for GBM amino acid metabolism. BMC Cancer 2017. 17:162.
Panosyan E, Lasky J, Lin H, Lai A, Hai Y, Guo X, Quinn M, Nelson SF, Cloughesy T, Nghiemphu P. “Clinical Aggressiveness of Malignant Gliomas is linked to Augmented Metabolism of Amino Acids”. J Neurooncol. 2016 May; 128(1): 57–66.
Panosyan EH, Wang Y, Xia P, Lee PW, Pak Y, Laks DR, Lin HJ, Moore TB, Cloughesy TF, Kornblum HI, and Lasky JL. Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy Against Brain Tumors. Mol Cancer Res. 2014 May; 12(5): 694–702.
Lasky JL 3rd, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB. Autologous Tumor Lysate-pulsed Dendritic Cell Immunotherapy for Pediatric Patients with Newly Diagnosed or Recurrent High-grade Gliomas. Anticancer Res. 2013 May;33(5):2047-56.